GLAXOSMITHKLINE plans to establish its third center for vaccine research and development in Rockville, Md. The site follows existing R&D centers in Rixensart, Belgium and Siena, Italy, which GSK acquired from Novartis in March.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe